The study's lead author said the findings may show something similar to the "obesity paradox," where high-risk patients fare better than expected due to frequent follow-up by physicians.
A study being presented this week at the American College of Cardiology (ACC) 66th Scientific Session finds that for some patients, having high systolic blood pressure does not lead to a higher risk of death, even though there are important implications for managed care.
The study, involving the Gulf-CARE registry and funded by Servier, a French pharmaceutical company, examined health records of 2492 patients with type 2 diabetes (T2D) who were among 5005 hospitalized with acute heart failure in 7 Middle Eastern countries: Oman, Saudia Arabia, Yemen, Kuwait, Qatar, Bahrain, and United Arab Emirates.
Results show that patients with both T2D and acute heart failure had a lower risk of death—but a higher risk of heart-related hospitalization—if they had high systolic blood pressure when discharged from the hospital, when compared with those with normal blood pressure. Although this study does not involve US health records, it’s worth looking at the results given that Medicare and many commercial health plans in the United States closely scrutinize 30-day readmission rates, and hospitals can face penalties for failing to meet targets in this area.
A statement from the ACC said this was the first study to examine blood pressure and health outcomes among people with T2D and among those with heart failure. Those with systolic blood pressure above 150 mmHg were 45% less likely to die, but 47% more likely to be hospitalized for heart failure during a 12-month follow up period. A normal systolic blood pressure reading should be lower than 140 mmHg in patients with diabetes, and lower than 130 mmHg in everyone else.
However, patients suffering from both conditions may have a “distinct pathophysiology of the heart and may benefit from different guidelines,” said lead study author Charbel Abi Khalil, MD, PhD, assistant professor of medicine and genetic medicine at Weill Cornell Medicine and cardiology consultant at the heart hospital Hamad Medical Corporation in Doha, Qatar.
Abi Khalil speculated that the results may point to a “blood pressure paradox,” which could be similar to a phenomenon known as the “obesity paradox,” in which patients with obesity and T2D have better survival that those without. Because this is an association and not a cause and effect, it’s been speculated that this may occur because these patients are followed more closely by physicians, and the same may be true of patients with heart failure and diabetes. The frequent follow-ups may suggest more care by cardiologists and diabetes specialists, along with early diagnosis of other health problems.
Semaglutide Eligibility Expands to Over Half of US Adults
November 21st 2024Over half of the US adult population may benefit from semaglutide, a drug primarily used for weight loss and diabetes, although concerns about access and cost persist, especially considering its potential for wider health applications.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Community Investment, Engagement Are Essential to Fully Address Cardiovascular Health Disparities
November 19th 2024Community-based researchers can teach clinicians a lot about how to best approach underserved populations disproportionately impacted by cardiovascular health complications.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen